Administration of oligonucleotides

A method for preventing or treating a disease associated with, or caused by, RAGE in a subject, the method comprising:

• in a first administration, administering to the respiratory tract of the subject an antisense oligonucleotide (AON) that that promotes the production of endogenous soluble RAGE and/or reduces the production of membrane bound RAGE (mRAGE),
• in a second administration, administering to the respiratory tract of the subject AON that promotes the production of endogenous soluble RAGE and/or reduces the production of membrane bound RAGE (mRAGE),
• wherein the second administration is at least about 7 days after the first administration,
• thereby preventing or treating a disease associated with, or caused by, RAGE in a subject.

A method for promoting the production of endogenous soluble RAGE and/or reducing the production of membrane bound RAGE (mRAGE) in a subject, the method comprising:

• in a first administration, administering to the respiratory tract of the subject an antisense oligonucleotide (AON) that promotes the production of endogenous soluble RAGE and/or reduces the production of membrane bound RAGE (mRAGE),
• in further administrations, administering to the respiratory tract of the subject an AON that promotes the production of endogenous soluble RAGE and/or reduces the production of membrane bound RAGE (mRAGE),
• wherein each further administration is at least about 7 days after the previous administration,
• thereby promoting the production of endogenous soluble RAGE and/or reducing the production of membrane bound RAGE (mRAGE) in a subject.

A method for preventing or treating a disease associated with, or caused by, RAGE in a subject, the method comprising:

• in a first administration, administering to the respiratory tract of the subject an antisense oligonucleotide (AON) that promotes the production of endogenous soluble RAGE and/or reduces the production of membrane bound RAGE (mRAGE),
• in further administrations, administering to the respiratory tract of the subject an AON that promotes the production of endogenous soluble RAGE and/or reduces the production of membrane bound RAGE (mRAGE),
• wherein each further administration is at least about 7 days after the first administration or previous administration,
• thereby preventing or treating a disease associated with, or caused by, RAGE in a subject.